文献速递睡眠呼吸障碍

中枢性睡眠呼吸暂停的病理生理、病因与管理更新

Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea.
PubMed 文献 · Respirology · 2026-07-24

本文综述了周期性呼吸型中枢性睡眠呼吸暂停(CSA)的病理生理、病因及管理。CSA常见于晚期心力衰竭或慢性阿片类药物使用,约5%的OSA患者启动CPAP时出现。各病因有特征性呼吸模式,管理应针对病因,但残余CSA的治疗选择存在争议。

要点

  • CSA常见于晚期心衰或慢性阿片类使用,约5%OSA患者启动CPAP时出现。
  • 慢性CPAP使用者突发CSA可能提示心房颤动。
  • 管理应针对病因,残余CSA的治疗选择存在争议。

核心结论

  • 周期性呼吸型CSA常见于晚期心衰或慢性阿片类使用,管理应针对病因。
  • 残余CSA的治疗选择存在争议,ASV在射血分数降低的心衰中观察到死亡率增加。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 在成人海平面,CSA最常见于晚期心衰或慢性阿片类使用,约5%的OSA患者启动CPAP时出现。
  • 慢性CPAP使用者的OSA患者突发CSA可能提示心房颤动。
  • 特发性CSA需排除心脏、神经和内分泌病因。
  • 每种CSA病因具有特征性的呼吸暂停、过度通气和周期长度表现。
  • 高原诱导的CSA与规律呼吸相比减少呼吸做功并维持气体交换,可能为适应性而非有害。

关键数值与推荐

  • 约5%的OSA患者启动CPAP时出现CSA。

临床怎么用

  • CSA管理应针对病因。
  • 残余CSA的治疗选择存在争议,包括呼吸兴奋剂(如乙酰唑胺)、正压通气(如ASV)、补充氧气或膈神经起搏。
  • ASV在射血分数降低的心衰中观察到死亡率增加,推荐缺乏强有力依据。

局限性

  • ASV等治疗推荐缺乏强有力依据,尤其在心衰射血分数降低患者中观察到死亡率增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Central sleep apnoea (CSA) of the periodic breathing type occurs during the transition between wakefulness and stage 1 and 2 non-REM sleep. In adults at sea level, it occurs most commonly due to advanced heart failure (HF) or chronic opioid use and in ~5% of obstructive sleep apnoea patients initiating CPAP. The sudden development of CSA in a chronic CPAP user for obstructive sleep apnoea (OSA) may indicate the development of atrial fibrillation. Less commonly, idiopathic CSA occurs in which cardiac, neurological and endocrine causes should be excluded. Each cause of CSA has a characteristic appearance of apnoea, hyperpnoea and cycle length. Altitude induced CSA has recently been shown to reduce work of breathing whilst maintaining gas exchange, compared with regular breathing and thereby be considered adaptive rather than detrimental. The management of each type of CSA should be directed at the cause. Where there is residual CSA (e.g., post intensive treatment for HF), debate exists as to the next option. One argument is that CSA is adaptive (as seen with altitude) and therapeutic. An alternative argument is to treat the CSA directly with therapies such as respiratory stimulants (e.g., acetazolamide), positive airway pressure (e.g., adaptive servo-ventilation (ASV)), supplemental oxygen or phrenic nerve pacing. These four latter treatments remain speculative without strong foundations for recommending especially ASV in HF with reduced ejection fraction where increased mortality has been observed.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Chandrasekara SD, Naughton MT. Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea. Respirology. 2026. PMID: 42498524. doi:10.1002/resp.70286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。